Living Cell Technologies Limited
Company Announcement

LCT Approved for DIABECELL® Clinical Trial in Argentina

- **LCT's clinical trial program expanded to third jurisdiction**
- **Argentina Phase II trial planned to commence in 2H 2011**
- **Clinical data growing to support DIABECELL as a treatment to normalise the lives of people with insulin-dependent diabetes**

3 May 2011: Sydney, Australia & Auckland, New Zealand. Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) a global company pioneering the development of a cell implant to treat diabetes, has obtained approval to commence a Phase II DIABECELL clinical trial in Buenos Aires, Argentina, DIABECELL's third jurisdiction to date which has approved human trials. Up to eight adult patients with Type 1 diabetes, including those with unstable diabetes and severe hypoglycaemia, will each receive two implants of DIABECELL, three months apart with a dose seeking component. The trial is expected to begin in the second half of this year.

The trial has received ethical approval from the relevant Bioethics authority of the Eva Perón Hospital in San Martín, Argentina (Comité de Investigación y Comité de Bioética del Hospital Eva Perón de San Martín), the approval of the Central Ethics Committee of the Minister of Health of the Buenos Aires Province (CEC), CUCAIBA, the coordinating committee for transplantation in Buenos Aires (Centro Unico Coordinador de Ablación e Implante de la Prov. de Bs. As.), and the Minister of Health of the Buenos Aires Province, Dr Alejandro Collia.

Dr Adrian Abalovich, MD, has been appointed principal investigator of the Argentinean trial, with Dr Boris Draznin, MD, PhD, Professor of Medicine, Endocrinology, and Diabetes at the University of Colorado Health Sciences Center agreeing to provide external supervision of the trial.

The Argentinean trial approval follows a positive assessment from the New Zealand Data Safety and Monitoring Board of the first twelve patients to receive DIABECELL implants in its Phase II trial in New Zealand, as well as favourable two-year follow up data from its Phase I/IIa clinical trial in Russia. LCT was recently granted registration of DIABECELL as a medical technology in Russia, and has announced plans for collaborative development of DIABECELL in Asia following the strategic investments made in LCT by ASK in China and Otsuka in Japan.

Professor Bob Elliott, LCT's Medical Director, said: "Dr Abalovich, the principal investigator for the proposed trial in Argentina, has a published record as a researcher in the area of porcine islet implantation. He provides excellent leadership of a group who will expand the dose seeking trials of DIABECELL. The healthcare infrastructure in Argentina is one of the more sophisticated in Latin America with clinical trials run to international GCP standards."

DIABECELL is LCT's treatment designed to normalise the lives of people with insulin-dependent diabetes. DIABECELL comprises encapsulated porcine insulin-producing cells (islets) that are implanted into the abdomen of patients using a simple laparoscopic procedure, and work by self-regulating and efficiently secreting insulin in the patient's body. LCT's breakthrough proprietary encapsulation technology, IMMUPEL™, means that patients receiving DIABECELL treatment do not require immunosuppression after implantation.

Dr Ross Macdonald LCT's CEO concluded: "This trial is intended to build upon encouraging clinical data to date and will provide additional robust clinical information relevant to our future pivotal clinical study program. Strategically, the trial creates the potential for future commercialisation in a new jurisdiction."

– Ends –

For further information: www.lctglobal.com

At the Company:	**Media and investor enquiries:**
Prof Bob Elliott Medical Director Mob: +64 27 292 4177 Tel:+64 9 276 2690 belliott@lctglobal.com Ms Susanne Clay Chief Business Officer, Living Cell Technologies Ltd. Tel: +64 9 270 7954 Mobile: +64 21 418 833 sclay@lctglobal.com	Buchan Consulting Rebecca Wilson Tel: +61 3 9866 4722 Mobile: +61 417 382 391 rwilson@bcg.com.au

About Living Cell Technologies - www. lctglobal.com
Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company implants its lead product DIABECELL, microencapsulated islet cells, in an effort to address the shortcomings of existing insulin therapy. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells, NTCELL, which delivers beneficial proteins and neurotrophic factors to the brain. LCT's breakthrough microencapsulation technology, IMMUPEL, enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer
This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional

analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.